| Line Item | 2024-03-31 | Y/Y |
|---|---|---|
| Revenue | $2.50B | +31.4% |
| Cost of Revenue | $1.69B | +4.4% |
| Gross Profit | $813.0M | +183.3% |
| R&D Expense | $42.4M | +95.9% |
| SG&A Expense | $183.6M | +89.5% |
| Operating Income | $587.1M | +248.5% |
| Pre-tax Income | $608.0M | +259.6% |
| Income Tax | $111.8M | +134.1% |
| Net Income | $306.2M |
| Line Item | 2024-03-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $474.1M | +264.6% |
| Accounts Receivable | $382.7M | +41.1% |
| Inventory | $201.7M | +46.1% |
| Current Assets | $1.77B | +102.7% |
| Total Assets | $2.52B | +77.4% |
| Current Liabilities | $891.5M | +75.7% |
| Long-term Debt | $144.0M | -2.2% |
| Line Item | 2024-03-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $429.0M | +298.4% |
| Capital Expenditures | $6.2M | +93.5% |
| Investing Cash Flow | -$6.7M | -110.8% |
| Financing Cash Flow | -$78.3M | -2091.1% |
| Free Cash Flow | $422.8M | +304.7% |
| — |
| EPS (Basic) | $3.97 | — |
| EPS (Diluted) | $3.37 | — |
| Total Liabilities |
| $1.53B |
| +63.3% |
| Stockholders' Equity | $961.0M | +131.2% |